PHIBRO ANIMAL HEALTH CORP
PHIBRO ANIMAL HEALTH CORP (PAHC): 6 pipeline candidates · ~12 mo cash runway. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
11.9 months
D/E 2.99
Lead: Approved
6 candidates
N/A
1 buy · 81 sells (180d)
A transparent, data-derived signal for PHIBRO ANIMAL HEALTH CORPacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.3B
Cash
$54.9M
Quarterly Burn
$81.0M
Runway
11.9 mo
Revenue
$383.5M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (6 candidates)
| Drug | Phase |
|---|---|
| atopic dermatitis compound | Preclinical |
| mitral heart valve disease treatment | Preclinical |
| novel pain management product | Preclinical |
| oral care formulations | Preclinical |
| potential treatment for mitral valve disease in dogs | Preclinical |
| rejensa | Approved |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
258
Total value held
$1.07B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 3,253,848 | $180.0M |
| fmr llc | 2,173,126 | $120.2M |
| vanguard capital management llc | 1,782,566 | $98.6M |
| state street corp | 950,033 | $52.5M |
| geode capital management, llc | 604,648 | $33.4M |
| renaissance technologies llc | 576,735 | $31.9M |
| dimensional fund advisors lp | 507,852 | $28.1M |
| vanguard portfolio management llc | 490,342 | $27.1M |
| morgan stanley | 391,187 | $21.6M |
| invesco ltd. | 330,977 | $18.3M |
Showing top 10 of 258 institutional holders of PHIBRO ANIMAL HEALTH CORP. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in PHIBRO ANIMAL HEALTH CORP's pipeline?
PHIBRO ANIMAL HEALTH CORP (PAHC) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is PHIBRO ANIMAL HEALTH CORP's lead drug candidate?
PHIBRO ANIMAL HEALTH CORP's most advanced tracked candidate is atopic dermatitis compound (Preclinical) for Atopic dermatitis in dogs.
What is PHIBRO ANIMAL HEALTH CORP's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, PHIBRO ANIMAL HEALTH CORP has approximately 11.9 months of cash runway.
What is PHIBRO ANIMAL HEALTH CORP's market capitalization?
PHIBRO ANIMAL HEALTH CORP's market capitalization is approximately $1.3B.
Who is the CEO of PHIBRO ANIMAL HEALTH CORP?
Mr. Jack Clifford Bendheim is the chief executive officer of PHIBRO ANIMAL HEALTH CORP (PAHC).
Get the full picture on PHIBRO ANIMAL HEALTH CORP
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.